Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.42 |
| ▸ | STAT3 | P40763 | 1/20 | 0.42 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | F2 | P00734 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | NR4A2 | P43354 | 3/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | ALPL | P05186 | 3/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 2/20 | 0.37 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL983844 | 0.79 | L3MBTL1 (0.48) | NPSR1ALDH1A1L3MBTL1KDM4EMAPT | |
| SCHEMBL20567149 | 0.79 | LMNA (0.40) | NPSR1ALDH1A1KMT2A | |
| SCHEMBL15701735 | 0.79 | — | — | |
| SCHEMBL19763311 | 0.78 | KDM4C (0.48) | NPSR1ALDH1A1L3MBTL1KDM4CKDM4E | |
| SCHEMBL69295 | 0.78 | NPSR1 (0.48) | NPSR1ALDH1A1L3MBTL1KDM4CKDM4E | |
| SCHEMBL5761874 | 0.78 | NPSR1 (0.48) | NPSR1ALDH1A1L3MBTL1KDM4CKDM4E | |
| SCHEMBL2658385 | 0.77 | — | — | |
| SCHEMBL950773 | 0.77 | — | — | |
| SCHEMBL15051421 | 0.77 | GAA (0.49) | ALDH1A1L3MBTL1KDM4ESTAT3HIF1A | |
| SCHEMBL13726965 | 0.76 | NPSR1 (0.46) | NPSR1ALDH1A1L3MBTL1KDM4CKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4739393-A1 | TETRAHYDROQUINAZOLINE DERIVATIVES AS SELECTIVE CYTOTOXIC AGENTS | Merck Sharp & Dohme LLC (US) | 2026-05-13 | — | — | EP | disclosed |
| US-20260078130-A1 | NAMPT MODULATORS, PREPARATIONS, AND USES THEREOF | SIRONAX LTD (KY) | 2026-03-19 | — | — | US | disclosed |
| EP-4590674-A1 | NAMPT MODULATORS, PREPARATIONS, AND USES THEREOF | Sironax Ltd (KY) | 2025-07-30 | — | — | EP | disclosed |
| US-20250026759-A1 | TETRAHYDROQUINAZOLINE DERIVATIVES AS SELECTIVE CYTOTOXIC AGENTS | MERCK SHARP & DOHME LLC (US) | 2025-01-23 | — | — | US | disclosed |
| WO-2025014788-A1 | TETRAHYDROQUINAZOLINE DERIVATIVES AS SELECTIVE CYTOTOXIC AGENTS | MERCK SHARP & DOHME LLC (US) | 2025-01-16 | — | — | WO | disclosed |
| US-20240182445-A1 | MODULATORS OF TREK (TWIK RELATED K+ CHANNELS) CHANNEL FUNCTION | ONO PHARMACEUTICAL CO., LTD. (JP) | 2024-06-06 | — | — | US | disclosed |
| WO-2024061340-A1 | NAMPT MODULATORS, PREPARATIONS, AND USES THEREOF | Sironax Ltd. (KY) | 2024-03-28 | — | — | WO | disclosed |
| EP-4048659-A1 | MODULATORS OF TREK (TWIK RELATED K+ CHANNELS) CHANNEL FUNCTION | ONO Pharmaceutical Co., Ltd. (JP) | 2022-08-31 | — | — | EP | disclosed |
| WO-2021080015-A1 | MODULATORS OF TREK (TWIK RELATED K+ CHANNELS) CHANNEL FUNCTION | ONO PHARMACEUTICAL CO., LTD. (JP) | 2021-04-29 | — | — | WO | disclosed |
| WO-2021080015-A1 | MODULATORS OF TREK (TWIK RELATED K+ CHANNELS) CHANNEL FUNCTION | ONO PHARMACEUTICAL CO., LTD. (JP) | 2021-04-29 | — | — | WO | disclosed |
| US-20210101885-A1 | PROCESSES FOR THE PREPARATION OF PYRAZOLE DERIVATIVES USEFUL AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR | ARENA PHARMACEUTICALS, INC. | 2021-04-08 | — | — | US | disclosed |
| US-10787437-B2 | Processes for the preparation of pyrazole derivatives useful as modulators of the 5-HT2A serotonin receptor | ARENA PHARMACEUTICALS, INC. (US) | 2020-09-29 | — | — | US | disclosed |
| US-20190023691-A1 | PROCESSES FOR THE PREPARATION OF PYRAZOLE DERIVATIVES USEFUL AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR | ARENA PHARMACEUTICALS, INC. | 2019-01-24 | — | — | US | disclosed |
| US-10059691-B2 | Processes for the preparation of pyrazole derivatives useful as modulators of the 5-HT2A serotonin receptor | ARENA PHARMACEUTICALS, INC. (US) | 2018-08-28 | — | — | US | disclosed |
| US-20170137408-A1 | PROCESSES FOR THE PREPARATION OF PYRAZOLE DERIVATIVES USEFUL AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR | ARENA PHARMACEUTICALS, INC. | 2017-05-18 | — | — | US | disclosed |
| US-9556149-B2 | Processes for the preparation of pyrazole derivatives useful as modulators of the 5-HT2A serotonin receptor | ARENA PHARMACEUTICALS, INC. (US) | 2017-01-31 | — | — | US | disclosed |
| US-20150045372-A1 | PROCESSES FOR THE PREPARATION OF PYRAZOLE DERIVATIVES USEFUL AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR | ARENA PHARMACEUTICALS, INC. | 2015-02-12 | — | — | US | disclosed |
| WO-2012126791-A1 | 1,4-OXAZEPINES AS BACE1 AND/OR BACE2 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-09-27 | — | — | WO | disclosed |
| US-20110021538-A1 | PROCESSES FOR THE PREPARATION OF PYRAZOLE DERIVATIVES USEFUL AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR | ARENA PHARMACEUTICALS, INC. (US) | 2011-01-27 | — | — | US | disclosed |
| WO-2009123714-A2 | PROCESSES FOR THE PREPARATION OF PYRAZOLE DERIVATIVES USEFUL AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR | ARENA PHARMACEUTICALS, INC. (US) | 2009-10-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10787437-B2 | Processes for the preparation of pyrazole derivatives useful as modulators of the 5-HT2A serotonin receptor | HTR5A, HTR2A, HTR3A | NPSR1 33/4885ALDH1A1 1106/4885L3MBTL1 4884/4885 |
| US-20150045372-A1 | PROCESSES FOR THE PREPARATION OF PYRAZOLE DERIVATIVES USEFUL AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR | HTR5A, HTR2A, HTR3A | NPSR1 33/4885ALDH1A1 1106/4885L3MBTL1 4884/4885 |
| US-20170137408-A1 | PROCESSES FOR THE PREPARATION OF PYRAZOLE DERIVATIVES USEFUL AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR | HTR5A, HTR2A, HTR3A | NPSR1 33/4885ALDH1A1 1106/4885L3MBTL1 4884/4885 |
| US-20260078130-A1 | NAMPT MODULATORS, PREPARATIONS, AND USES THEREOF | NAMPT, NNMT, SARM1 | NPSR1 298/4885ALDH1A1 2719/4885L3MBTL1 2991/4885 |
| US-20210101885-A1 | PROCESSES FOR THE PREPARATION OF PYRAZOLE DERIVATIVES USEFUL AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR | HTR5A, HTR2A, HTR3A | NPSR1 33/4885ALDH1A1 1106/4885L3MBTL1 4884/4885 |
| US-20240182445-A1 | MODULATORS OF TREK (TWIK RELATED K+ CHANNELS) CHANNEL FUNCTION | KCNJ11, KCNJ1, KCNJ2 | NPSR1 2573/4885ALDH1A1 2944/4885L3MBTL1 2910/4885 |
| US-20190023691-A1 | PROCESSES FOR THE PREPARATION OF PYRAZOLE DERIVATIVES USEFUL AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR | HTR5A, HTR2A, HTR3A | NPSR1 33/4885ALDH1A1 1106/4885L3MBTL1 4884/4885 |
| US-20250026759-A1 | TETRAHYDROQUINAZOLINE DERIVATIVES AS SELECTIVE CYTOTOXIC AGENTS | ACIN1, REV1, NFATC1 | NPSR1 4707/4885ALDH1A1 3081/4885L3MBTL1 1341/4885 |
| US-20110021538-A1 | PROCESSES FOR THE PREPARATION OF PYRAZOLE DERIVATIVES USEFUL AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR | HTR5A, HTR2A, HTR3A | NPSR1 33/4885ALDH1A1 1106/4885L3MBTL1 4884/4885 |
| US-10059691-B2 | Processes for the preparation of pyrazole derivatives useful as modulators of the 5-HT2A serotonin receptor | HTR5A, HTR2A, HTR3A | NPSR1 33/4885ALDH1A1 1106/4885L3MBTL1 4884/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.